SAN FRANCISCO -- Two mainstream devices for percutaneous left atrial appendage (LAA) closure continued to lead to similar clinical outcomes in the SWISS-APERO trial. Among patients randomized to the ...

Boston Scientific, Inc. BSX recently announced receiving the FDA approval for the latest-generation WATCHMAN FLX Pro Left Atrial Appendage Closure (LAAC) Device. The latest device is intended to ...

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...

A Watchman is a device that can help prevent blood clots from leaving the heart. However, the procedure to insert the device carries its risks, including cardiac tamponade and ischemic stroke. The ...

New stroke risk reduction therapy with thromboresistant coating is designed to advance procedural performance and safety MARLBOROUGH, Mass., Sept. 6, 2023 /PRNewswire/ -- Boston Scientific Corporation ...

Columbus Regional Health Heart & Vascular announced that its cardiovascular services team recently completed its 100th Watchman™ procedure, which treats patients with atrial fibrillation (AFib).

MARLBOROUGH, Mass., Sept. 6, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has received U.S. Food and Drug Administration approval for the latest-generation ...